Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Infections
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Zinforo
Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: Complicated skin and soft tissue infections (cSSTI) Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents.
View on EMAMigraine Without Aura
Anxiety Disorders
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
ST Elevation Myocardial Infarction
Generalized Anxiety Disorder